1. Home
  2. SLNHP vs ERNAW Comparison

SLNHP vs ERNAW Comparison

Compare SLNHP & ERNAW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Soluna Holdings Inc 9.0% Series A Cumulative Perpetual Preferred Stock

SLNHP

Soluna Holdings Inc 9.0% Series A Cumulative Perpetual Preferred Stock

N/A

Current Price

$11.20

Market Cap

0.0

Sector

Technology

ML Signal

N/A

Logo Ernexa Therapeutics Inc. Warrants

ERNAW

Ernexa Therapeutics Inc. Warrants

N/A

Current Price

$0.03

Market Cap

0.0

Sector

N/A

ML Signal

N/A

Company Overview

Basic Information
Metric
SLNHP
ERNAW
Founded
N/A
N/A
Country
United States
United States
Employees
N/A
N/A
Industry
EDP Services
Sector
Technology
Exchange
Nasdaq
Nasdaq
Market Cap
N/A
N/A
IPO Year
2005
2021

Fundamental Metrics

Financial Performance
Metric
SLNHP
ERNAW
Price
$11.20
$0.03
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
5.6K
★ 25.4K
Earning Date
N/A
N/A
Dividend Yield
N/A
N/A
EPS Growth
★ 80.41
31.29
EPS
★ N/A
N/A
Revenue
★ $38,021,000.00
$582,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
★ N/A
N/A
Revenue Growth
★ 80.49
N/A
52 Week Low
$6.30
$0.02
52 Week High
$12.91
$0.23

Technical Indicators

Market Signals
Indicator
SLNHP
ERNAW
Relative Strength Index (RSI) 49.49 44.74
Support Level $10.98 $0.02
Resistance Level $11.50 $0.08
Average True Range (ATR) 0.82 0.01
MACD 0.07 0.00
Stochastic Oscillator 92.84 22.61

Price Performance

Historical Comparison
SLNHP
ERNAW

About SLNHP Soluna Holdings Inc 9.0% Series A Cumulative Perpetual Preferred Stock

Soluna Holdings Inc is a U.S.-based company engaged in the development and operation of data centers powered by renewable energy. The company utilizes excess or curtailed energy from renewable sources to support high-performance computing applications, including cryptocurrency mining, artificial intelligence, and machine learning. Its business model focuses on converting underutilized renewable energy into computing resources through co-located data center infrastructure.

About ERNAW Ernexa Therapeutics Inc. Warrants

Ernexa Therapeutics Inc is a preclinical-stage synthetic allogeneic iMSC therapy company developing medicines to treat various forms of cancer and other diseases with high unmet medical needs. Its main product candidate, ERNA-101, capitalizes on the intrinsic tumor-homing ability of MSCs (mesenchymal stem cells) to slip through the tumor's defenses and to deliver potent pro-inflammatory factors directly to the tumor microenvironment. The firm's initial focus is to develop ERNA-101 in platinum-resistant ovarian cancer. Through another product candidate, ERNA-201, it is investigating anti-inflammatory cytokine (IL-10) secreting iMSCs in autoimmune disorders like rheumatoid arthritis. The company operates in a single reportable segment, the research and development of cellular therapies.

Share on Social Networks: